药明生物:中金上调目标价至 22.5 港元

和讯网
17 Jan

【中金上调药明生物目标价至 22.5 港元,预计今年业务呈加速态势】中金发布报告称,药明生物CEO 陈智胜在第 43 届摩根大通医疗健康大会上,向投资者更新了业务近况及 2025 年展望。公司维持 2024 年指引不变,包括 5 至 10%收入增长,8 至 14%扣新冠收入增长,并预计 2025 年业务加速。由于新签项目数量强劲增长,PPQ 项目储备丰富有望放量,中金上调 2024 至 2026 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10